4results about How to "Improve powder properties" patented technology

This invention discloses a *Lactobacillus plantarum* bacterial powder, its preparation method, and its application. The wall material of the bacterial powder includes resistant starch, whey protein, and a heat protectant. The bacterial cells in the powder are *Lactobacillus plantarum* TH103. The mass percentages of resistant starch, whey protein, and the heat protectant are 7-23%, with the total mass percentage of resistant starch and whey protein being 3-15% and the mass percentage of the heat protectant being 4-8%. The viable count of the bacterial powder is (3.5-9.0) × 10⁻⁶. 9 The CFU / g and moisture content are 5-7%. This invention uses resistant starch and whey protein as protective carriers, supplemented with heat-resistant protective agents, to achieve the preparation of *Lactobacillus plantarum* powder by spray drying. The obtained *Lactobacillus plantarum* powder has a viable count and moisture content that meet the relevant requirements for probiotic foods, and has good powder properties. It can be directly brewed in powder form or applied to fermented foods such as yogurt.

The invention relates to a composition and a preparation process of a 20 (S)-protopanoxadiol (20 (S)-protopanoxadiol, 20 (S)-PPD) phospholipid / mesoporous silicon solid dispersion, and belongs to the technical field of medicines. The invention provides a 20 (S)-PPD phospholipid / mesoporous silicon solid dispersion preparation. The preparation consists of 20 (S)-PPD, phospholipid, ethanol, a crystal inhibitor and a dispersing agent. The preparation disclosed by the invention is prepared by adopting a solvent evaporation method; the prepared 20 (S)-PPD phospholipid / meso-porous silicon solid dispersion is good in stability; the drug loading capacity is high, and the content of 20 (S)-PPD in the preparation can reach 40% or above; and the absolute bioavailability of oral administration is high and can reach 23.95%. After the preparation is orally taken, the injury of podocyte for maintaining the integrity of a glomerular filtration barrier can be remarkably relieved, and adult chronic nephrotic syndromes such as membranous nephropathy (MN) can be treated.

The invention belongs to the field of chemical medicines, and particularly relates to a novel crystal form of a rerugolil 2-methyltetrahydrofuran solvate, and the novel crystal form of rerugolil 2-methyltetrahydrofuran is a crystal form alpha. Compared with an existing crystal form, the crystal form has high solubility and excellent powder property, is beneficial to storage and operation in a production process, is low in impurity content, and is beneficial to purification of a rugolix crude product and feeding in a refining step.

The invention belongs to the field of chemical medicines, and particularly relates to a novel crystal form of a rerugolil 2-methyltetrahydrofuran solvate, and the novel crystal form of rerugolil 2-methyltetrahydrofuran is a crystal form beta. Compared with an existing crystal form, the crystal form has high solubility and excellent powder property, is beneficial to storage and operation in a production process, is low in impurity content, and is beneficial to purification of a rugolix crude product and feeding in a refining step.